Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.86 |
| ▸ | MAPK12 | P53778 | 16/20 | 0.86 |
| ▸ | HCK | P08631 | 15/20 | 0.86 |
| ▸ | SRC | P12931 | 2/20 | 0.81 |
| ▸ | TNF | P01375 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086867 | 1.00 | MAPK14 (0.86) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL2408004 | 0.92 | MAPK14 (1.00) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL19841214 | 0.91 | MAPK14 (0.71) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL299715 | 0.90 | MAPK14 (0.85) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL29593973 | 0.90 | MAPK14 (0.85) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL2404321 | 0.90 | MAPK14 (0.82) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL6727041 | 0.90 | MAPK14 (0.87) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL2573234 | 0.89 | MAPK14 (1.00) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL17017152 | 0.89 | MAPK14 (0.75) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL2406152 | 0.89 | MAPK14 (0.84) | MAPK14MAPK12HCKSRCTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634406-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2023-04-25 | — | — | US | disclosed |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| CN-113264921-A | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20210179584-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2021-06-17 | — | — | US | disclosed |
| CN-106573914-B | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10815217-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2020-10-27 | — | — | US | disclosed |
| EP-3357919-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS | RESPIVERT LTD (GB) | 2019-11-20 | — | — | EP | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD. (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD. (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| US-20110269800-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110269800-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-2370428-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-09-01 | — | — | US | disclosed |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-09-01 | — | — | US | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | MAP3K1, MAP3K2, MAP3K8 | MAPK14 18/4885MAPK12 43/4885HCK 773/4885 |
| US-20110269800-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K11, MAP3K1 | MAPK14 22/4885MAPK12 23/4885HCK 733/4885 |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, TTK | MAPK14 418/4885MAPK12 634/4885HCK 1/4885 |
| US-10815217-B2 | Inhibitor of p38 MAP kinase | MAPK1, MAPKAPK2, MAP3K1 | MAPK14 5/4885MAPK12 34/4885HCK 274/4885 |
| US-20210179584-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPKAPK2, MAPK10 | MAPK14 9/4885MAPK12 27/4885HCK 812/4885 |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | MAPK14 10/4885MAPK12 13/4885HCK 348/4885 |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | MAPK14 12/4885MAPK12 37/4885HCK 730/4885 |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | MAPK14 33/4885MAPK12 31/4885HCK 2830/4885 |
| US-11634406-B2 | Inhibitor of p38 MAP kinase | MAPK1, MAPKAPK2, MAPK10 | MAPK14 9/4885MAPK12 27/4885HCK 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.